Phase 1/2 Study of Rilotumumab (AMG 102), a Hepatocyte Growth Factor Inhibitor, and Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Article

International Collaboration

cited authors

  • Tarhini, Ahmad A.; Rafique, Imran; Floros, Theofanis; Tran, Phu; Gooding, William E.; Villaruz, Liza C.; Burns, Timothy F.; Friedland, David M.; Petro, Daniel P.; Farooqui, Mariya; Gomez-Garcia, Jose; Gaither-Davis, Autumn; Dacic, Sanja; Argiris, Athanassios; Socinski, Mark A.; Stabile, Laura P.; Siegfried, Jill M.

authors

Publication Date

  • August 1, 2017

webpage

published in

category

keywords

  • amphiregulin
  • epidermal growth factor receptor (EGFR)
  • erlotinib
  • hepatocyte growth factor (HGF)
  • mesenchymal-epidermal transition factor (c-MET)
  • neuregulin 1
  • non-small cell lung cancer (NSCLC)
  • rilotumumab (AMG 102)

start page

  • 2936

end page

  • 2944

volume

  • 123

issue

  • 15